SCHEMBL6931695

SCHEMBL6931695

COc1ccc(OC(F)(F)F)cc1CC1CCCN(N)C1c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 18/20 0.52
KCNH2 Q12809 2/20 0.52
CYP2D6 P10635 1/20 0.52
HTR1A P08908 1/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
HRH1 P35367 1/20 0.52
HTR2B P41595 1/20 0.52
SLC6A3 Q01959 1/20 0.52
TMEM97 Q5BJF2 1/20 0.52
SIGMAR1 Q99720 1/20 0.52
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6700500 1.00 TACR1 (0.52) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL4913542 1.00 TACR1 (0.52) TACR1KCNH2CYP2D6HTR1AHTR2A
Hydrochloric Acid SCHEMBL4913478 0.99 TACR1 (0.53) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL9420083 0.95 TACR1 (0.51) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL8694736 0.90 TACR1 (0.54) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL6153291 0.89 TACR1 (0.54) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL9420084 0.89 MEN1 (0.43) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL4918429 0.89 TACR1 (0.45) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL7254534 0.89 TACR1 (0.43) TACR1KCNH2CYP2D6HTR1AHTR2A
SCHEMBL4915866 0.89 TACR1 (0.45) TACR1KCNH2CYP2D6HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017395-A4 METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME MERCK & CO INC (US) 2003-06-04 EP disclosed
EP-1030672-A1 METHOD FOR TREATING ATTENTION DEFICIT DISORDER Merck & Co., Inc. (US) 2000-08-30 EP disclosed
EP-1017395-A1 METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME Merck & Co., Inc. (US) 2000-07-12 EP disclosed
WO-1999059583-A1 METHOD FOR TREATING OR PREVENTING CHRONIC NONBACTERIAL PROSTATITIS AND PROSTATODYNIA MERCK & CO., INC. (US) 1999-11-25 WO disclosed
WO-1999027938-A1 METHOD FOR TREATING OR PREVENTING PSYCHOSOMATIC AND PSYCHOIMMUNOLOGIC DISORDERS MERCK & CO., INC. (US) 1999-06-10 WO disclosed
WO-1999025364-A1 METHOD FOR TREATING ATTENTION DEFICIT DISORDER MERCK & CO., INC. (US) 1999-05-27 WO disclosed
WO-1999009987-A1 METHOD FOR TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME MERCK & CO., INC. (US) 1999-03-04 WO disclosed